Biography
Dr. dr. Gestina Aliska, Sp.FK is a clinical pharmacologist and lecturer at FK UNAND, with research spanning pharmacogenomics, sepsis, and COVID-19. Her recent publications appear in Heliyon (2024), European J. of Pharmacology (2023), and OAMJMS, covering glucocorticoid pathways, antiviral outcomes, and cardiovascular biomarkers. She leads research on MDR pathogens, biomarker expression, and drug monitoring. She has presented at IUPHAR and The Union, and authored educational materials on drug interactions and clinical pharmacology. A recipient of the Satya Lencana Karya Satya award (2024), she is active in PERDAFKI and IKAFI, and manages clinical research at FK UNAND.
Key Impacts
Hepatoprotective role of N-acetylcysteine in anti-TB drug-induced hepatotoxicity: A meta-analysis of controlled clinical studies
NAC significantly lowered the risk of ATDH and improved liver biochemical profiles in patients undergoing anti-TB therapy. Given its safety, affordability, and ease of administration, NAC may be considered an adjunctive protective agent, particularly in high-risk populations. Further well-designed, large-scale, randomized controlled trials are warranted to confirm these findings and optimize clinical implementation.
Source: Conference 2024
Drug–drug interactions between antiretroviral and anti-TB therapy in adults and children: A systematic review of pharmacokinetic and clinical outcomes
This review highlights consistent pharmacokinetic risks across age groups and drug classes. Efavirenz remains the most robust ARV for adult TB co-treatment. Nevirapine and dolutegravir require careful monitoring or adjustment. Personalized ART guided by age and pharmacogenetics is essential to optimize TB–HIV outcomes.
Source: Conference 2024